WUXI BIO has announced its interim results for the 2026 fiscal year, showcasing robust growth across its operations. The company reported revenue of RMB 11.787 billion, marking an 18.4% increase year-over-year, with gross profit climbing 28.1% to RMB 5.448 billion.

Net profit attributable to shareholders reached RMB 2.44 billion, a 4.3% improvement from the prior year, while adjusted net profit surged 38.4% to RMB 3.306 billion. Basic earnings per share stood at RMB 0.60.

The revenue growth reflects comprehensive expansion across all project stages and regional markets, driven primarily by robust demand for new IND-enabling projects, the steady advancement of multiple projects into later-stage clinical development and commercial manufacturing, and solid growth in the North American market. During the reporting period, the company's integrated end-to-end CRDMO platform, combined with its "follow and win the molecule" strategy, continued to fuel steady portfolio expansion.

As of June 30, 2026, WUXI BIO had added 169 new integrated projects, bringing the total to 1,064. Among these, late-stage clinical and commercial manufacturing projects grew to 78 and 28, respectively. Additionally, the company secured 16 external projects through its "win the molecule" initiative, including four late-stage clinical programs and one commercial manufacturing project, providing further momentum for future growth.